Literature DB >> 16175405

Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle.

Susan E Best1, Philip M Sarrel, Robert T Malison, Marc Laruelle, Sami S Zoghbi, Ronald M Baldwin, John P Seibyl, Robert B Innis, Christopher H van Dyck.   

Abstract

OBJECTIVES: The effect of gender and female menstrual cycle on human striatal dopamine transporters (DATs) was investigated with single-photon emission computed tomography (SPECT) using the ligand 2beta-carbomethoxy-3beta-(4-[(123)I]iodophenyl)tropane.
METHODS: Ten female subjects aged 18-40 years (25.3+/-7.3 years) were scanned twice during the early follicular and the mid-luteal phases to detect any hormone-mediated changes in DAT availability in the striatum or serotonin transporter (SERT) availability in brainstem-diencephalon. Plasma estradiol and progesterone levels were obtained at the time of SPECT and confirmed the expected increases from the follicular to the luteal phases. Finally, in a post hoc analysis of a previously published healthy-subject sample, striatal DAT availability was compared between 70 male and 52 female subjects who ranged in age from 18 to 88 years.
RESULTS: In the ten menstrual cycle subjects, DAT availability (V(3)'') in striatum and SERT availability in brainstem-diencephalon did not differ between follicular and luteal phases. Moreover, change in V(3)'' for striatum or brainstem-diencephalon was uncorrelated with change in plasma estradiol or progesterone from the follicular to the luteal phase. In the larger healthy-subject sample, there was no significant effect of gender or the interaction of age and gender on striatal V(3)''.
CONCLUSIONS: These findings suggest that in using DAT or SERT ligands in the study of neuropsychiatric disorders, matching of female subjects according to a menstrual cycle phase is unnecessary. Although the present investigation did not confirm previous reports of gender differences in striatal DAT availability, controlling for gender in such studies still seems advisable.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16175405     DOI: 10.1007/s00213-005-0158-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  52 in total

1.  Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.

Authors:  M Laruelle; A Abi-Dargham; C van Dyck; R Gil; D C D'Souza; J Krystal; J Seibyl; R Baldwin; R Innis
Journal:  Biol Psychiatry       Date:  2000-03-01       Impact factor: 13.382

2.  The role of estrogen in schizophrenia.

Authors:  M V Seeman
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

3.  Platelet 3H-imipramine binding and steroid hormones serum concentrations during the menstrual cycle.

Authors:  M F Poirier; C Benkelfat; A M Galzin; S Z Langer
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites.

Authors:  M Laruelle; M A Vanisberg; J M Maloteaux
Journal:  Biol Psychiatry       Date:  1988-07       Impact factor: 13.382

5.  The human corpus striatum and dentate nucleus: volumetric analysis for hemispheric asymmetries, sex differences, and aging changes.

Authors:  G M Murphy
Journal:  Exp Neurol       Date:  1985-07       Impact factor: 5.330

6.  Gender differences in substance use disorders.

Authors:  K T Brady; D E Grice; L Dustan; C Randall
Journal:  Am J Psychiatry       Date:  1993-11       Impact factor: 18.112

7.  Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT.

Authors:  R T Malison; S E Best; C H van Dyck; E F McCance; E A Wallace; M Laruelle; R M Baldwin; J P Seibyl; L H Price; T R Kosten; R B Innis
Journal:  Am J Psychiatry       Date:  1998-06       Impact factor: 18.112

Review 8.  Modulation of brain dopamine transmission by sex steroids.

Authors:  T Di Paolo
Journal:  Rev Neurosci       Date:  1994 Jan-Mar       Impact factor: 4.353

9.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.

Authors:  R B Innis; J P Seibyl; B E Scanley; M Laruelle; A Abi-Dargham; E Wallace; R M Baldwin; Y Zea-Ponce; S Zoghbi; S Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

10.  A PET study of D2 dopamine receptor density at different phases of the menstrual cycle.

Authors:  A L Nordström; H Olsson; C Halldin
Journal:  Psychiatry Res       Date:  1998-07-15       Impact factor: 3.222

View more
  16 in total

1.  The relationship between subcortical brain volume and striatal dopamine D2/3 receptor availability in healthy humans assessed with [11 C]-raclopride and [11 C]-(+)-PHNO PET.

Authors:  Fernando Caravaggio; Jun Ku Chung; Eric Plitman; Isabelle Boileau; Philip Gerretsen; Julia Kim; Yusuke Iwata; Raihaan Patel; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Hum Brain Mapp       Date:  2017-07-28       Impact factor: 5.038

2.  Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects.

Authors:  Alexandre Eusebio; Jean-Philippe Azulay; Mathieu Ceccaldi; Nadine Girard; Olivier Mundler; Eric Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-14       Impact factor: 9.236

Review 3.  Contributions of neuroimaging to understanding sex differences in cocaine abuse.

Authors:  Monica L Andersen; Eileen K Sawyer; Leonard L Howell
Journal:  Exp Clin Psychopharmacol       Date:  2011-08-29       Impact factor: 3.157

Review 4.  PET studies in nonhuman primate models of cocaine abuse: translational research related to vulnerability and neuroadaptations.

Authors:  Robert W Gould; Angela N Duke; Michael A Nader
Journal:  Neuropharmacology       Date:  2013-02-28       Impact factor: 5.250

5.  Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender.

Authors:  Henricus G Ruhé; Jan Booij; Johannes B Reitsma; Aart H Schene
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-30       Impact factor: 9.236

6.  Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: a beta-CIT imaging study.

Authors:  Richard F Seegal; Kenneth L Marek; John P Seibyl; Danna L Jennings; Eric S Molho; Donald S Higgins; Stewart A Factor; Edward F Fitzgerald; Elaine A Hills; Susan A Korrick; Mary S Wolff; Richard F Haase; Andrew C Todd; Patrick Parsons; Robert J McCaffrey
Journal:  Neurobiol Dis       Date:  2010-01-20       Impact factor: 5.996

Review 7.  Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs.

Authors:  Jan Booij; Paul Kemp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-30       Impact factor: 9.236

8.  [I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects.

Authors:  Walter Koch; Nadine Schaaff; Gabriele Pöpperl; Christoph Mulert; Georg Juckel; Markus Reicherzer; Christoff Ehmer-von Geiso; Hans-Jürgen Möller; Ulrich Hegerl; Klaus Tatsch; Oliver Pogarell
Journal:  J Psychiatry Neurosci       Date:  2007-07       Impact factor: 6.186

9.  Prenatal stress induces increased striatal dopamine transporter binding in adult nonhuman primates.

Authors:  Alexander K Converse; Colleen F Moore; Jeffrey M Moirano; Elizabeth O Ahlers; Julie A Larson; Jonathan W Engle; Todd E Barnhart; Dhanabalan Murali; Bradley T Christian; Onofre T DeJesus; James E Holden; Robert J Nickles; Mary L Schneider
Journal:  Biol Psychiatry       Date:  2013-05-29       Impact factor: 13.382

Review 10.  Evolving knowledge of sex differences in brain structure, function, and chemistry.

Authors:  Kelly P Cosgrove; Carolyn M Mazure; Julie K Staley
Journal:  Biol Psychiatry       Date:  2007-06-04       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.